Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
Recruiting
Medical College of Wisconsin
Phase 2
2017-06-14
This is a prospective phase II clinical study to be conducted at the Medical College of
Wisconsin. After meeting the study criteria and enrollment, patients will be treated with
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic
intervals to determine the primary and secondary objectives.
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
Active, not recruiting
Merck KGaA, Darmstadt, Germany
Phase 4
2018-05-28
The main purpose of the study was to determine the onset of Mavenclad® action by frequent
magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in
participants with highly active relapsing multiple sclerosis (MS).
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
Active, not recruiting
Merck KGaA, Darmstadt, Germany
Phase 4
2018-06-20
The main purpose of the study is to assess the health-related quality of life (HRQoL) through
the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active
relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months).
Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
Recruiting
Medical College of Wisconsin
Phase 1
2018-05-22
This is a prospective, single-center phase I clinical study aimed at determining the
maximum-tolerated dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy
in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design
to estimate the maximum-tolerated dose (MTD).
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
Recruiting
Göteborg University
Phase 3
2019-10-16
The main aim and overall objective of the study is to assess whether rituximab is
non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators
will test specific blood and MRI biomarkers that may contribute to future personalized
treatment for MS patients. Furthermore, the investigators want to evaluate the health
economic consequences of the two therapies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
